Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 HeskaMyriad GeneticsLantheusCelldex TherapeuticsMeridian Bioscience
SymbolNASDAQ:HSKANASDAQ:MYGNNASDAQ:LNTHNASDAQ:CLDXNASDAQ:VIVO
Price Information
Current Price$176.98$28.16$21.04$20.71$25.04
52 Week RangeBuyHoldBuyBuyBuy
MarketRank™
Overall Score1.41.01.71.81.7
Analysis Score2.50.92.43.53.5
Community Score2.41.92.53.11.9
Dividend Score0.00.00.00.00.0
Ownership Score1.71.71.71.71.7
Earnings & Valuation Score0.60.61.90.61.3
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$217.50$21.00$23.67$35.50$33.00
% Upside from Price Target22.90% upside-25.43% downside12.48% upside71.41% upside31.79% upside
Trade Information
Market Cap$1.84 billion$2.12 billion$1.41 billion$820.43 million$1.08 billion
Beta1.651.711.322.960.59
Average Volume87,115829,549562,273722,481799,578
Sales & Book Value
Annual Revenue$122.66 million$638.60 million$347.34 million$3.57 million$253.67 million
Price / Sales15.033.324.06229.814.26
Cashflow$1.06 per share$0.70 per share$2.10 per shareN/A$1.60 per share
Price / Cash166.7140.3210.04N/A15.64
Book Value$19.72 per share$12.32 per share$2.92 per share$5.83 per share$5.78 per share
Price / Book8.972.297.213.554.33
Profitability
Net Income$-1,470,000.00$-199,500,000.00$31.67 million$-50,880,000.00$46.19 million
EPS$0.05($0.35)$1.17($3.28)$1.07
Trailing P/E RatioN/AN/A263.03N/A23.19
Forward P/E RatioN/AN/A42.94N/A23.40
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-11.15%-32.49%0.12%-1,069.42%18.21%
Return on Equity (ROE)-2.29%-4.07%11.05%-30.93%21.06%
Return on Assets (ROA)-1.64%-2.68%5.43%-26.55%12.55%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.18%0.25%0.40%N/A0.28%
Current Ratio4.96%2.95%2.25%16.63%3.09%
Quick Ratio3.79%2.75%1.79%16.63%1.92%
Ownership Information
Institutional Ownership Percentage96.11%96.72%84.95%80.15%88.33%
Insider Ownership Percentage11.70%2.80%2.08%2.40%2.00%
Miscellaneous
Employees6022,700595123750
Shares Outstanding10.42 million75.21 million67.03 million39.62 million43.15 million
Next Earnings Date5/6/2021 (Confirmed)5/4/2021 (Estimated)4/29/2021 (Estimated)5/5/2021 (Estimated)5/14/2021 (Estimated)
OptionableNot OptionableOptionableOptionableOptionableOptionable
SourceHeadline
Meridian Bioscience: Good Stock, But Margin Of Safety RequiredMeridian Bioscience: Good Stock, But Margin Of Safety Required
seekingalpha.com - April 9 at 4:15 PM
Meridian Bioscience (NASDAQ:VIVO) Downgraded by Zacks Investment ResearchMeridian Bioscience (NASDAQ:VIVO) Downgraded by Zacks Investment Research
marketbeat.com - April 8 at 6:44 AM
Vivo X60 Pro is Now Available for Sale in PakistanVivo X60 Pro is Now Available for Sale in Pakistan
propakistani.pk - April 7 at 8:37 AM
Meridian Bioscience Stock Shows Every Sign Of Being Modestly OvervaluedMeridian Bioscience Stock Shows Every Sign Of Being Modestly Overvalued
gurufocus.com - April 7 at 3:34 AM
Meridian Bioscience (NASDAQ:VIVO)  Shares Down 3.6% Meridian Bioscience (NASDAQ:VIVO) Shares Down 3.6%
americanbankingnews.com - April 6 at 12:02 PM
vivo’s Latest 5G Flagship Smartphone X60 Pro is Now Available For Sale in Pakistanvivo’s Latest 5G Flagship Smartphone X60 Pro is Now Available For Sale in Pakistan
phoneworld.com.pk - April 6 at 7:11 AM
4 Lucrative MedTech Stocks to Bet On in 2021 Amid Pandemic4 Lucrative MedTech Stocks to Bet On in 2021 Amid Pandemic
finance.yahoo.com - April 1 at 2:55 PM
Meridian Bioscience (NASDAQ:VIVO) Shares Up 7.6%Meridian Bioscience (NASDAQ:VIVO) Shares Up 7.6%
americanbankingnews.com - April 1 at 11:36 AM
VIVO Cannabis(TM) Announces Fourth Quarter 2020 ResultsVIVO Cannabis(TM) Announces Fourth Quarter 2020 Results
stockhouse.com - April 1 at 9:54 AM
Meridian Bioscience Announces FDA Submission for New Curian® Campy AssayMeridian Bioscience Announces FDA Submission for New Curian® Campy Assay
finance.yahoo.com - April 1 at 9:54 AM
IBD 50 Stocks To Watch: This Biotech Stock With 282% Earnings Growth Nears Buy PointIBD 50 Stocks To Watch: This Biotech Stock With 282% Earnings Growth Nears Buy Point
finance.yahoo.com - March 31 at 6:52 PM
Biomerica (NASDAQ:BMRA) versus Meridian Bioscience (NASDAQ:VIVO) Head to Head SurveyBiomerica (NASDAQ:BMRA) versus Meridian Bioscience (NASDAQ:VIVO) Head to Head Survey
americanbankingnews.com - March 27 at 8:20 PM
Heres Why You Should Add Haemonetics (HAE) to Your PortfolioHere's Why You Should Add Haemonetics (HAE) to Your Portfolio
finance.yahoo.com - March 24 at 12:47 PM
Meridian Bioscience Inc (VIVO) CEO John P. Kenny Sold $750,000 of SharesMeridian Bioscience Inc (VIVO) CEO John P. Kenny Sold $750,000 of Shares
finance.yahoo.com - March 18 at 12:08 PM
Dont Ignore The Fact That This Insider Just Sold Some Shares In Meridian Bioscience, Inc. (NASDAQ:VIVO)Don't Ignore The Fact That This Insider Just Sold Some Shares In Meridian Bioscience, Inc. (NASDAQ:VIVO)
nasdaq.com - March 17 at 4:04 PM
Meridian Bioscience (VIVO) Presents At H.C. Wainwright Global Life Sciences 2021 Virtual Conference - SlideshowMeridian Bioscience (VIVO) Presents At H.C. Wainwright Global Life Sciences 2021 Virtual Conference - Slideshow
seekingalpha.com - March 15 at 11:36 PM
Meridian Biosciences (VIVO) Shares March Higher, Can It Continue?Meridian Bioscience's (VIVO) Shares March Higher, Can It Continue?
finance.yahoo.com - March 11 at 1:32 PM
Did You Miss Meridian Biosciences (NASDAQ:VIVO) Impressive 189% Share Price Gain?Did You Miss Meridian Bioscience's (NASDAQ:VIVO) Impressive 189% Share Price Gain?
finance.yahoo.com - March 9 at 12:49 PM
Meridian Launches its New Air-Dryable Mix for Crude Blood Samples Nasdaq:VIVOMeridian Launches its New Air-Dryable Mix for Crude Blood Samples Nasdaq:VIVO
compsmag.com - March 8 at 3:10 PM
Meridian Launches its New Air-Dryable Mix for Crude Blood SamplesMeridian Launches its New Air-Dryable Mix for Crude Blood Samples
finance.yahoo.com - March 8 at 10:10 AM
Meridian Bioscience to Participate in H.C. Wainwright Global Life Sciences 2021 Virtual ConferenceMeridian Bioscience to Participate in H.C. Wainwright Global Life Sciences 2021 Virtual Conference
finance.yahoo.com - March 4 at 11:43 AM
Here is Why Growth Investors Should Buy Meridian Bioscience (VIVO) NowHere is Why Growth Investors Should Buy Meridian Bioscience (VIVO) Now
finance.yahoo.com - March 1 at 5:20 PM
Meridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV-2 EUA WithdrawalMeridian Bioscience Corrects Prior Update Regarding Revogene® SARS-CoV-2 EUA Withdrawal
markets.businessinsider.com - February 23 at 5:39 PM
SHAREHOLDER ALERT: Meridian Bioscience, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the FirmSHAREHOLDER ALERT: Meridian Bioscience, Inc. Investigated for Possible Securities Laws Violations by Block & Leviton LLP; Investors Should Contact the Firm
finance.yahoo.com - February 23 at 5:39 PM
Meridian Bioscience corrects prior update on Revogene sars-cov-2 EUA withdrawalMeridian Bioscience corrects prior update on Revogene sars-cov-2 EUA withdrawal
seekingalpha.com - February 23 at 1:29 PM
Meridian Bioscience Provides a Further Update on the Revogene® SARS-CoV-2 EUA SubmissionMeridian Bioscience Provides a Further Update on the Revogene® SARS-CoV-2 EUA Submission
finance.yahoo.com - February 23 at 12:38 PM
DateCompanyBrokerageAction
3/3/2021HeskaRaymond JamesBoost Price Target
3/1/2021HeskaPiper SandlerBoost Price Target
2/24/2021HeskaAlliance Global PartnersReiterated Rating
1/29/2021HeskaJPMorgan Chase & Co.Initiated Coverage
3/27/2020HeskaSidotiLower Price Target
11/6/2019HeskaCanaccord GenuityReiterated Rating
9/18/2019HeskaPiper Jaffray CompaniesInitiated Coverage
5/23/2019HeskaGuggenheimInitiated Coverage
2/27/2019HeskaB. RileyLower Price Target
3/2/2021Myriad GeneticsSVB LeerinkBoost Price Target
8/14/2020Myriad GeneticsNeedham & Company LLCReiterated Rating
4/2/2020Myriad GeneticsBank of AmericaLower Price Target
3/26/2020Myriad GeneticsBarclaysLower Price Target
8/14/2019Myriad GeneticsDeutsche Bank AktiengesellschaftLower Price Target
3/4/2021LantheusCredit Suisse GroupBoost Price Target
6/29/2020LantheusJefferies Financial GroupInitiated Coverage
6/16/2020LantheusCJS SecuritiesUpgrade
8/2/2018LantheusWells Fargo & CompanyLower Price Target
3/1/2021Celldex TherapeuticsHC WainwrightBoost Price Target
2/23/2021Celldex TherapeuticsCantor FitzgeraldBoost Price Target
11/17/2020Celldex TherapeuticsLifesci CapitalReiterated Rating
8/9/2018Celldex TherapeuticsCowenReiterated Rating
5/11/2020Meridian BioscienceWilliam BlairUpgrade
4/3/2019Meridian BioscienceRobert W. BairdLower Price Target
(Data available from 4/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.